Target family: Poly ADP-ribosylating PARPs (type: enzyme)
Target: poly(ADP-ribose) polymerase 1

Ligand: AG14361 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 8.239999771118164 pKi
Reference (Journal): Tricyclic benzimidazoles as potent poly(ADP-ribose) polymerase-1 inhibitors.
Published in: J Med Chem

Ligand: AZ1366 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.25 pIC50
Reference (Journal): Pyrimidinone nicotinamide mimetics as selective tankyrase and wnt pathway inhibitors suitable for in vivo pharmacology.
Published in: ACS Med Chem Lett

Ligand: AZD9574 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.300000190734863 pIC50
Reference (Patent): Quinoxaline derivatives as anti-cancer drugs

Ligand: ciclopirox (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1982)
Primary target: no
Median affinity: 6.800000190734863 pIC50
Reference (Journal): Identification of ring-fused pyrazolo pyridin-2-ones as novel poly(ADP-ribose)polymerase-1 inhibitors.
Published in: Bioorg Med Chem Lett

Ligand: compound 10b [PMID: 26222319] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.059999942779541 pKd
Reference (Journal): Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy.
Published in: J Med Chem

Ligand: compound 5 [Tomassi et al., 2020] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.050000190734863 pIC50
Reference (Journal): From PARP1 to TNKS2 Inhibition: A Structure-Based Approach
Published in: ACS Med Chem Lett

Ligand: compound 9 [Lin et al., 2023] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Synthesis of Novel Dual Target Inhibitors of CDK12 and PARP1 and Their Antitumor Activities in HER2-Positive Breast Cancers
Published in: ACS Omega

Ligand: dual VEGFR/PARP inhibitor 14b (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.21999979019165 pIC50
Reference (Journal): Discovery, Synthesis, and Evaluation of Novel Dual Inhibitors of a Vascular Endothelial Growth Factor Receptor and Poly(ADP-Ribose) Polymerase for BRCA Wild-Type Breast Cancer Therapy.
Published in: J Med Chem

Ligand: KU0058948 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.71999979019165 pKd
Reference (Journal): Structural basis for inhibitor specificity in human poly(ADP-ribose) polymerase-3.
Published in: J Med Chem

Ligand: lerzeparib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.550000190734863 pIC50
Reference (Patent): Indolo heptamyl oxime analogue as parp inhibitor

Ligand: MC2050 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.920000076293945 pIC50
Reference (Journal): Biological effects of MC2050, a quinazoline-based PARP-1 inhibitor, in human neuroblastoma and EBV-positive Burkitt's lymphoma cells.
Published in: ChemMedChem

Ligand: MC2050 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.029999732971191 pIC50
Reference (Journal): From PARP1 to TNKS2 Inhibition: A Structure-Based Approach
Published in: ACS Med Chem Lett

Ligand: ME0328 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.199999809265137 pIC50
Reference (Journal): Chemical probes to study ADP-ribosylation: synthesis and biochemical evaluation of inhibitors of the human ADP-ribosyltransferase ARTD3/PARP3.
Published in: J Med Chem

Ligand: niraparib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: EMA & FDA (2017)
Primary target: yes
Median affinity: 8.420000076293945 pIC50
Reference (Journal): Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors.
Published in: J Med Chem

Ligand: olaparib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: EMA & FDA (2014)
Primary target: yes
Median affinity: 8.300000190734863 pIC50
Reference (Journal): 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1.
Published in: J Med Chem

Ligand: olaparib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: EMA & FDA (2014)
Primary target: yes
Median affinity: 8.300000190734863 pIC50
Reference (Journal): A FlashPlate assay for the identification of PARP-1 inhibitors.
Published in: J Biomol Screen

Ligand: pamiparib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: China (2021)
Primary target: no
Median affinity: 8.890000343322754 pIC50
Reference (Journal): Discovery of Pamiparib (BGB-290), a Potent and Selective Poly (ADP-ribose) Polymerase (PARP) Inhibitor in Clinical Development.
Published in: J Med Chem

Ligand: PJ34 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.699999809265137 pIC50
Reference (Journal): Identification of ring-fused pyrazolo pyridin-2-ones as novel poly(ADP-ribose)polymerase-1 inhibitors.
Published in: Bioorg Med Chem Lett

Ligand: rucaparib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (2016), EMA (2018)
Primary target: yes
Median affinity: 8.850000381469727 pKi
Reference (Journal): Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial.
Published in: Mol Cancer Ther

Ligand: saruparib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 8.399999618530273 pIC50
Reference (Patent): PARP1 INHIBITORS

Ligand: talazoparib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (2018), EMA (2019)
Primary target: yes
Median affinity:  -
Reference (Journal): Structural basis for the inhibition of poly(ADP-ribose) polymerases 1 and 2 by BMN 673, a potent inhibitor derived from dihydropyridophthalazinone.
Published in: Acta Crystallogr F Struct Biol Commun

Ligand: venadaparib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.300000190734863 pIC50
Reference (Patent): A novel phtalazinone derivatives and manufacturing process thereof